On Sept. 30, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System had been CE marked to the IVD Directive.

The test, available in the U.S. since July through an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA), uses the BD Veritor Plus System, which is already in use across Europe to test for conditions such as Group A Strep, influenza A+B and Respiratory Syncytial Virus.